SSTR2 in Nasopharyngeal Carcinoma: Relationship with Latent EBV Infection and Potential as a Therapeutic Target.
Oscar EmanuelJacklyn LiuVolker Hans SchartingerWen Long NeiYuk Yu ChanChi Man TsangHerbert RiechelmannLiam MastersonJohannes HaybaeckUdo OppermannStefan M WillemsMarc L OoftGuido WollmannDavid HowardBart VanhaesebroeckValerie J LundGary RoyleMatthew Chin Heng ChuaKwok-Wai LoPierre BussonMatt LechnerPublished in: Cancers (2021)
Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor, most commonly located in the pharyngeal recess and endemic to parts of Asia. It is often detected at a late stage which is associated with poor prognosis (5-year survival rate of 63%). Treatment for this malignancy relies predominantly on radiotherapy and/or systemic chemotherapy, which can be associated with significant morbidity and impaired quality of life. In endemic regions NPC is associated with infection by Epstein-Barr virus (EBV) which was shown to upregulate the somatostatin receptor 2 (SSTR2) cell surface receptor. With recent advances in molecular techniques allowing for an improved understanding of the molecular aetiology of this disease and its relation to SSTR2 expression, we provide a comprehensive and up-to-date overview of this disease and highlight the emergence of SSTR2 as a key tumor biomarker and promising target for imaging and therapy.